Results 11 to 20 of about 22,047 (159)

Critical Analysis of Apixaban Dose Adjustment Criteria

Clinical and Applied Thrombosis/Hemostasis, 2021
Apixaban is indicated for the prevention of ischemic stroke in non-valvular atrial fibrillation (NVAF), as well as for the prevention and treatment of venous thromboembolism (VTE).
Anh Vu PharmD, Tao T. Qu PharmD, Rachel Ryu PharmD, BCPS, Shuktika Nandkeolyar MD, Alan Jacobson MD, Lisa T. Hong PharmD, BCPS   +5 more
doaj   +1 more source

Population pharmacokinetics of apixaban in a real‐life hospitalized population from the OptimAT study

CPT: Pharmacometrics & Systems Pharmacology, 2023
This study aimed to characterize apixaban pharmacokinetics (PKs) and its variability in a real‐world clinical setting of hospitalized patients using a population PK (PopPK) approach. Model‐based simulations helped to identify factors that affect apixaban
Frédéric Gaspar, Jean Terrier, Samantha Favre, Pauline Gosselin, Pierre Fontana, Youssef Daali, Camille Lenoir, Caroline Flora Samer, Victoria Rollason, Jean‐Luc Reny, Chantal Csajka, Monia Guidi   +11 more
doaj   +1 more source

Apixaban as a Rare Cause of Leukocytoclastic Vasculitis

Case Reports in Rheumatology, 2020
Apixaban is a rare cause of leukocytoclastic vasculitis (LCV). To our knowledge, there is only one other reported case due to apixaban in the literature. We present a case of apixaban-induced leukocytoclastic vasculitis in a 95-year-old male. He had been
Jenna Spears, David Alexandre Chetrit, Sina Manthey, Christopher Lee, Yousif Al-Saiegh   +4 more
doaj   +1 more source

Plasma apixaban levels in Chinese patients with chronic kidney disease—Relationship with renal function and bleeding complications

Frontiers in Pharmacology, 2022
Introduction: Accumulation of apixaban in plasma is a major concern in patients with chronic kidney disease (CKD). Studies that investigated plasma apixaban level in CKD patients and its association with clinically significant events are scarce.Methods ...
Chun-fung Sin, Ka-ping Wong, Ka-ping Wong, Tsz-fu Wong, Chung-wah Siu, Desmond Y. H. Yap   +5 more
doaj   +1 more source

The influence of residual apixaban on bleeding complications during and after catheter ablation of atrial fibrillation

Journal of Arrhythmia, 2017
Background: The periprocedural protocol for atrial fibrillation (AF) ablation commonly includes anticoagulation therapy. Apixaban, a direct oral anticoagulant, is currently approved for clinical use; however, little is known about the effects of residual
Yutaro Mukai, Kyoichi Wada, Koji Miyamoto, Kazuki Nakagita, Mai Fujimoto, Kouichi Hosomi, Takeshi Kuwahara, Mitsutaka Takada, Kengo Kusano, Akira Oita   +9 more
doaj   +1 more source

Does amiodarone impact on apixaban levels? The effect of amiodarone on apixaban level among Thai patients with non-valvular Atrial Fibrillation.

PLoS ONE
BackgroundApixaban and amiodarone are drugs used for non-valvular atrial fibrillation (NVAF) in routine practice. The evidence about apixaban plasma levels in patients who receive apixaban with amiodarone, including bleeding outcomes, has been limited ...
Sutee Limcharoen, Sarawuth Limprasert, Pornwalai Boonmuang, Manat Pongchaidecha, Juthathip Suphanklang, Weerayuth Saelim, Wichai Santimaleeworagun, Piyarat Pimsi   +7 more
doaj   +1 more source

Evaluation of safety, pharmacokinetics, and pharmacodynamics of apixaban in pediatric subjects at risk of venous or arterial thrombotic disorder

CPT: Pharmacometrics & Systems Pharmacology, 2023
Apixaban is an oral small‐molecule, direct factor Xa (FXa) inhibitor approved in adults for treatment of deep vein thrombosis and pulmonary embolism, and for reducing risk of venous thromboembolism recurrence after initial anticoagulant therapy.
Samira J. Merali, Wonkyung Byon, Yogesh T. Patel, Amira Elsrougy, David Marchisin, Vidya Perera, Weidong Chen, Bing He, Bindu Murthy   +8 more
doaj   +1 more source

Carbamazepine Induction Impacting Apixaban Concentrations: A Case ReportNovel Teaching Points

CJC Open, 2020
Avoidance of apixaban with carbamazepine (CBZ) is recommended owing to an anticipated reduction in apixaban concentration, although this drug interaction is poorly described. We report a case wherein apixaban concentration was measured before and 2 weeks
Tammy J. Bungard, BSP, PharmD, R. Neil Roberts, MD   +1 more
doaj   +1 more source

In vivo evaluation of the pharmacokinetic interactions between almonertinib and rivaroxaban, almonertinib and apixaban

Frontiers in Pharmacology, 2023
Background: Almonertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is commonly used as a first-line treatment for non-small cell lung cancer (NSCLC) patients with EGFR T790M mutations.
Zhi Wang, Ying Li, Xueru He, Yuhao Fu, Yajing Li, Xin Zhou, Zhanjun Dong   +6 more
doaj   +1 more source

Traumatic Pseudoaneursym of Superficial Temporal Artery in an Octogenarian Patient Under Apixaban Therapy

Hitit Medical Journal, 2020
An 80-year-old female was admitted to the hospital, presenting a pulsatile and painless mass on the right temporal site occurred one month ago following a blunt head trauma.
Sertan Özyalçın, Adem İlkay Diken, Adnan Yalçınkaya, Ufuk Türkmen   +3 more
doaj